Back

Analysis of cell-mediated immunity in people with long Covid.

Montes, N.; Domenech, E.; Guerrero, S.; Oliván-Blázquez, B.; Magallon-Botalla, R.

2021-06-09 allergy and immunology
10.1101/2021.06.09.21258553 medRxiv
Show abstract

IntroductionThe objective of this study is to analyse the specific immune response against SARS-CoV-2 in those affected by Long Covid (LC), attributable to T cells (cell-mediated immunity) and to carry out a parallel analysis of the humoral response and lymphocyte typing. MethodologyDescriptive cross-sectional study of 74 patients with LC for at least 4 months since diagnosis. The collected data were: information on the COVID-19 episode and the persistent symptoms, medical history and a specific cell-mediated immunity to SARS-CoV-2 through flow cytometry, assessing the release of interferon-gamma (IFN-{gamma}) by T4 lymphocytes, T8 lymphocytes and NK cells. Descriptive and comparative analyses were carried out. ResultsPatients with LC had negative serology for Covid-19 in 89% of cases but 96% showed specific cellular immunity to SARS-CoV-2 an average of 9.5 months after infection: 89% of this response corresponded to T8 lymphocytes, 58% to NK cells, and 51% to T4 lymphocyte (20% negligibly positive). Most of them had altered immune cell typing and we found that T4 lymphocyte counts were low in 34% of cases and NK cell high in 64%. Macrophage populations were detected in the peripheral blood of 7% of them. Patients displayed a higher percentage of illnesses related to &[Prime]abnormal&[Prime] immune responses, either preceding SARS-CoV-2 infection (43%) or following it in 23% of cases. ConclusionThe immune system appears to have an important involvement in the development of LC and viral persistence could be the cause or consequence of it. Further analysis with a control group should be performed.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 3%
28.6%
2
Journal of Medical Virology
137 papers in training set
Top 0.1%
23.3%
50% of probability mass above
3
Biology
43 papers in training set
Top 0.1%
3.7%
4
Frontiers in Immunology
586 papers in training set
Top 2%
3.7%
5
Vaccines
196 papers in training set
Top 0.6%
3.7%
6
Immunology
29 papers in training set
Top 0.2%
2.5%
7
Pharmaceuticals
33 papers in training set
Top 0.4%
2.1%
8
Medicine
30 papers in training set
Top 1%
1.7%
9
BMC Infectious Diseases
118 papers in training set
Top 3%
1.7%
10
International Journal of Medical Informatics
25 papers in training set
Top 0.9%
1.5%
11
Journal of Clinical Virology
62 papers in training set
Top 0.5%
1.4%
12
Journal of Clinical Medicine
91 papers in training set
Top 4%
1.3%
13
Journal of Translational Medicine
46 papers in training set
Top 2%
1.0%
14
Journal of Clinical Pathology
12 papers in training set
Top 0.3%
1.0%
15
Clinical Infectious Diseases
231 papers in training set
Top 4%
0.9%
16
Scientific Reports
3102 papers in training set
Top 72%
0.8%
17
Allergy
23 papers in training set
Top 0.7%
0.7%
18
Virologica Sinica
10 papers in training set
Top 0.5%
0.7%
19
Emerging Infectious Diseases
103 papers in training set
Top 3%
0.7%
20
Journal of Clinical Investigation
164 papers in training set
Top 7%
0.7%
21
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 1%
0.7%
22
EMBO Molecular Medicine
85 papers in training set
Top 5%
0.7%
23
Multiple Sclerosis and Related Disorders
15 papers in training set
Top 0.2%
0.7%
24
Journal of Molecular Cell Biology
21 papers in training set
Top 0.9%
0.7%
25
PeerJ
261 papers in training set
Top 17%
0.7%
26
Archives of Clinical and Biomedical Research
28 papers in training set
Top 3%
0.5%
27
Journal of Biomedical Science
14 papers in training set
Top 0.3%
0.5%